Drug Trial Radar · NCT04776226
Post-stroke Depression Treatment Effect on Stroke Recurrence
Last checked: Nov 19, 2026Latest source record: Mar 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,230
Actual
Start
Feb 11, 2017
Primary completion
Mar 10, 2018
Study completion Mar 30, 2019
Sponsor
- Lead sponsor
- Ege UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 1, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is not clear whether depresssion can predispose, or precipitate stroke recurrence in patients with stroke. We sought the relationship of post stroke depression with stroke recurrence.
Conditions
- Stroke Recurrence
- Cardiovascular Events
- Depression
Interventions
CitalopramDrug
Antidepressant use in patients with depression
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stroke recurrenceTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ege University
Izmir, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.